 Glycine
"Glycine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.
| Descriptor ID |
D005998
|
| MeSH Number(s) |
D12.125.481
|
| Concept/Terms |
Glycine- Glycine
- Aminoacetic Acid
- Acid, Aminoacetic
|
Below are MeSH descriptors whose meaning is more general than "Glycine".
Below are MeSH descriptors whose meaning is more specific than "Glycine".
This graph shows the total number of publications written about "Glycine" by people in UAMS Profiles by year, and whether "Glycine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2025 | 1 | 0 | 1 | | 2024 | 3 | 0 | 3 | | 2022 | 0 | 1 | 1 | | 2021 | 2 | 3 | 5 | | 2020 | 1 | 2 | 3 | | 2018 | 1 | 1 | 2 | | 2017 | 3 | 0 | 3 | | 2016 | 0 | 1 | 1 | | 2015 | 1 | 3 | 4 | | 2013 | 1 | 0 | 1 | | 2011 | 2 | 0 | 2 | | 2010 | 2 | 0 | 2 | | 2009 | 1 | 2 | 3 | | 2008 | 0 | 1 | 1 | | 2006 | 1 | 2 | 3 | | 2005 | 3 | 1 | 4 | | 2004 | 1 | 4 | 5 | | 2003 | 1 | 0 | 1 | | 2002 | 0 | 4 | 4 | | 1998 | 1 | 0 | 1 | | 1995 | 1 | 0 | 1 | | 1994 | 0 | 1 | 1 | | 1992 | 0 | 1 | 1 | | 1990 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Glycine" by people in Profiles over the past ten years.
-
Ahn JH, Guo Y, Lyons H, Mackintosh SG, Lau BK, Edmondson RD, Byrum SD, Storey AJ, Tackett AJ, Cai L, Sabari BR, Wang GG. The phenylalanine-and-glycine repeats of NUP98 oncofusions form condensates that selectively partition transcriptional coactivators. Mol Cell. 2025 Feb 20; 85(4):708-725.e9.
-
Voorhees P, Suman V, Efebera Y, Raje N, Tuchman S, Rodriguez C, Laubach J, Bova-Solem M, Carlisle D, Usmani S, McCarthy P, Richardson PG. Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse. Blood Adv. 2024 10 08; 8(19):5039-5050.
-
Lee HC, Ramasamy K, Macro M, Davies FE, Abonour R, van Rhee F, Hungria VTM, Puig N, Ren K, Silar J, Enwemadu V, Cherepanov D, Leleu X. Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study. Eur J Haematol. 2024 Aug; 113(2):190-200.
-
Deutz LN, Wierzchowska-McNew RA, Deutz NE, Engelen MP. Reduced plasma glycine concentration in healthy and chronically diseased older adults: a marker of visceral adiposity? Am J Clin Nutr. 2024 06; 119(6):1455-1464.
-
Molina-Santiago C, Udaondo Z. Mechanisms of resistance to glyphosate: an example of bacterial adaptability to anthropogenic substances. Environ Microbiol. 2022 08; 24(8):3313-3315.
-
Auner HW, Brown SR, Walker K, Kendall J, Dawkins B, Meads D, Morgan GJ, Kaiser MF, Cook M, Roberts S, Parrish C, Cook G. Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results. Blood Cancer J. 2022 04 01; 12(4):52.
-
Li H, Rajani V, Han L, Chung D, Cooke JE, Sengar AS, Salter MW. Alternative splicing of GluN1 gates glycine site-dependent nonionotropic signaling by NMDAR receptors. Proc Natl Acad Sci U S A. 2021 07 06; 118(27).
-
Davies F, Rifkin R, Costello C, Morgan G, Usmani S, Abonour R, Palumbo A, Romanus D, Hajek R, Terpos E, Cherepanov D, Stull DM, Huang H, Leleu X, Berdeja J, Lee HC, Weisel K, Thompson M, Boccadoro M, Zonder J, Cook G, Puig N, Vela-Ojeda J, Farrelly E, Raju A, Blazer M, Chari A. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Ann Hematol. 2021 Sep; 100(9):2325-2337.
-
Oltvai ZN, Harley SE, Koes D, Michel S, Warlick ED, Nelson AC, Yohe S, Mroz P. Assessing acquired resistance to IDH1 inhibitor therapy by full-exon IDH1 sequencing and structural modeling. Cold Spring Harb Mol Case Stud. 2021 04; 7(2).
-
H?jek R, Minar?k J, Straub J, Pour L, Jungova A, Berdeja JG, Boccadoro M, Brozova L, Spencer A, van Rhee F, Vela-Ojeda J, Thompson MA, Abonour R, Chari A, Cook G, Costello CL, Davies FE, Hungria VT, Lee HC, Leleu X, Puig N, Rifkin RM, Terpos E, Usmani SZ, Weisel KC, Zonder JA, Barinov? M, Kuhn M, ?ilar J, C?pkov? L, Galvez K, Lu J, Elliott J, Stull DM, Ren K, Maisnar V. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncol. 2021 Jul; 17(19):2499-2512.
-
Ziff M, Lawson G, De-Silva D, Cheesman S, Kyriakou C, Mahmood S, Papanikolaou X, Rabin N, Sachchithananthan S, Sive J, Wechalekar A, Yong K, Popat R. Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set. Leuk Lymphoma. 2021 05; 62(5):1243-1246.
-
Dimopoulos MA, ?picka I, Quach H, Oriol A, H?jek R, Garg M, Beksac M, Bringhen S, Katodritou E, Chng WJ, Leleu X, Iida S, Mateos MV, Morgan G, Vorog A, Labotka R, Wang B, Palumbo A, Lonial S. Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. J Clin Oncol. 2020 12 01; 38(34):4030-4041.
-
Nakamura N, Pence LM, Cao Z, Beger RD. Distinct lipid signatures are identified in the plasma of rats with chronic inflammation induced by estradiol benzoate and sex hormones. Metabolomics. 2020 09 07; 16(9):95.
-
Rajani V, Sengar AS, Salter MW. Tripartite signalling by NMDA receptors. Mol Brain. 2020 02 18; 13(1):23.
-
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019 01 19; 393(10168):253-264.
-
Zheng JH, Grace CR, Guibao CD, McNamara DE, Llambi F, Wang YM, Chen T, Moldoveanu T. Intrinsic Instability of BOK Enables Membrane Permeabilization in Apoptosis. Cell Rep. 2018 05 15; 23(7):2083-2094.e6.
-
Kim SY, Kaufman MJ, Cohen BM, Jensen JE, Coyle JT, Du F, ?ng?r D. In?Vivo Brain Glycine and Glutamate Concentrations in Patients With First-Episode Psychosis Measured by Echo Time-Averaged Proton Magnetic Resonance Spectroscopy at 4T. Biol Psychiatry. 2018 03 15; 83(6):484-491.
-
Yang Y, Lei H, Qiang YW, Wang B. Ixazomib enhances parathyroid hormone-induced ?-catenin/T-cell factor signaling by dissociating ?-catenin from the parathyroid hormone receptor. Mol Biol Cell. 2017 Jul 01; 28(13):1792-1803.
-
Tumber A, Nuzzi A, Hookway ES, Hatch SB, Velupillai S, Johansson C, Kawamura A, Savitsky P, Yapp C, Szykowska A, Wu N, Bountra C, Strain-Damerell C, Burgess-Brown NA, Ruda GF, Fedorov O, Munro S, England KS, Nowak RP, Schofield CJ, La Thangue NB, Pawlyn C, Davies F, Morgan G, Athanasou N, M?ller S, Oppermann U, Brennan PE. Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells. Cell Chem Biol. 2017 Mar 16; 24(3):371-380.
-
Alfadhel M, Nashabat M, Qahtani HA, Alfares A, Mutairi FA, Shaalan HA, Douglas GV, Wierenga K, Juusola J, Alrifai MT, Arold ST, Alkuraya F, Ali QA. Mutation in SLC6A9 encoding a glycine transporter causes a novel form of non-ketotic hyperglycinemia in humans. Hum Genet. 2016 Nov; 135(11):1263-1268.
-
Fang XQ, Qiao H, Groveman BR, Feng S, Pflueger M, Xin WK, Ali MK, Lin SX, Xu J, Duclot F, Kabbaj M, Wang W, Ding XS, Santiago-Sim T, Jiang XH, Salter MW, Yu XM. Regulated internalization of NMDA receptors drives PKD1-mediated suppression of the activity of residual cell-surface NMDA receptors. Mol Brain. 2015 Nov 19; 8(1):75.
-
Stockler-Ipsiroglu S, Apatean D, Battini R, DeBrosse S, Dessoffy K, Edvardson S, Eichler F, Johnston K, Koeller DM, Nouioua S, Tazir M, Verma A, Dowling MD, Wierenga KJ, Wierenga AM, Zhang V, Wong LJ. Arginine:glycine amidinotransferase (AGAT) deficiency: Clinical features and long term outcomes in 16 patients diagnosed worldwide. Mol Genet Metab. 2015 Dec; 116(4):252-9.
-
Smith EM, Zhang L, Walker BA, Davenport EL, Aronson LI, Krige D, Hooftman L, Drummond AH, Morgan GJ, Davies FE. The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NF?B signalling pathway. Oncotarget. 2015 Jul 10; 6(19):17314-27.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|